Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $860.6 billion.

  • Addex Therapeutics' Accumulated Expenses changed N/A to $860.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $860.6 billion, marking a year-over-year change of. This contributed to the annual value of $589.8 billion for FY2024, which is 4287706728.17% up from last year.
  • As of Q3 2025, Addex Therapeutics' Accumulated Expenses stood at $860.6 billion.
  • Addex Therapeutics' Accumulated Expenses' 5-year high stood at $860.6 billion during Q3 2025, with a 5-year trough of $1.4 million in Q4 2023.
  • For the 4-year period, Addex Therapeutics' Accumulated Expenses averaged around $363.2 billion, with its median value being $296.1 billion (2022).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 1607.11% in 2023, then skyrocketed by 4252755077.15% in 2024.
  • Quarter analysis of 4 years shows Addex Therapeutics' Accumulated Expenses stood at $1.7 million in 2022, then dropped by 16.07% to $1.4 million in 2023, then skyrocketed by 42527550.77% to $592.3 billion in 2024, then surged by 45.3% to $860.6 billion in 2025.
  • Its Accumulated Expenses stands at $860.6 billion for Q3 2025, versus $592.3 billion for Q4 2024 and $1.4 million for Q4 2023.